Tag: MASH
-
MASLD non-invasive tests — fibrosis staging clears the bar, the MASH treatment gate does not
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. In a prospective, multicenter cohort with centrally read liver biopsy as the reference standard (LITMUS Imaging Study, N = 357, Nature Medicine, published online July 24,…
-
Finerenone and the CKM “third pillar” — complementarity is a division of outcomes, and the anti-fibrotic expansion is preclinical-thick but human-empty
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. Finerenone completes the cardio-kidney-metabolic (CKM) “three-pillar” standard of care alongside SGLT2 inhibitors and GLP-1 agonists through a non-overlapping anti-inflammatory / anti-fibrotic axis. But the real substance…
Uthando Nethemba 